Japan Approves Keytruda, Leqembi SC Formulations, Xcopri, and More Drugs
To read the full story
Related Article
- Japan to List Eylea Biosimilars from SamChunDang, Celltrion on Nov. 13
November 12, 2026
- Keytruda SC Tops New NHI Listing Round with 75 Billion Yen Sales Outlook
November 9, 2026
- Xcopri, Leqembi SC Now in Line for Japan Approval with Panel Backing
August 27, 2026
- Keytruda SC Heads to Japan Approval, Ipsen’s Ojemda for Conditional Nod
August 25, 2026
REGULATORY
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
- Japan Grants Orphan Status to Rusfertide, Surovatamig, and Lots More
November 17, 2026
- Japan Extends Re-Examination for Saphnelo, Airwin, Fabhalta, Uplizna
November 17, 2026
- Takeda’s CLDN18.2 ADC Earns Sakigake Tag in Japan
November 17, 2026
- Japan Pharma Subgroup Talks to Feed into Pricing, Budget Debates
November 16, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





